Skip to content
Menu

IN8bio Presents Updated Clinical Data From INB-200 And INB-400 Programs In Newly Diagnosed GBM, In Oral Session At 2026 SNO Annual Meeting

Benzinga Newsdesk 6 hours ago

News

Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)50% of repeat-dose patients remained alive at two years, compared to 10%

Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)

50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group

Median progression-free survival (mPFS) of 13.0 months, nearly doubled the 6.6 months observed in the SOC control group

Favorable safety profile with no observed cytokine release syndrome (CRS), ICANS, major infections or treatment-related serious adverse events with up to six repeat doses of gamma-delta T cells

NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma (GBM), presented in an oral session at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia.

Read at benzinga.com